According to the FDA, the operators were procuring lower-cost medicines from other states and allegedly filling them into new ...
Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary ...
A federal appeals court has ruled that the U.S. Food and Drug Administration overstepped its authority by trying to require ...
Newspoint on MSN
K'taka FDA seizes spurious drugs worth Rs 4.91 crore, minister calls it 'national network'
Bengaluru: The Drug Enforcement Wing of the FDA has seized spurious and expired drugs worth over Rs 4.91 crore during an ...
Amylyx Pharmaceuticals (NasdaqGS: AMLX) reported overwhelmingly positive topline Phase 3 results for avexitide in ...
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the ...
At a Walgreens in San Francisco's bustling Japantown neighborhood, pharmacist Margaret On stocks two boxes of long-acting ...
Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise. Learn why RYTM stock is a buy.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results